DESCRIPTION
Exposure® Dermatological Anticellulite Cream with Liporeductyl® is
a unique liposomal formulation that fights and prevents unsightly
cellulite (localised lipodystrophy).
MAIN INGREDIENTS
Aqua, , ethylhexyl ethylhexanoate, glycerin, lecithin, caffeine,
ruscus aculeatus extract, tea-hydroiodide, hedera helix extract,
carnitine, escin, tripeptide-1, xantham gum, chondrus crispus,
dimethicone, methyl nicotinate, imidazolidinyl urea, disodium
edta, methylchloroisothiazolinone, methylisothiazolinone, phenoxyethanol.
INDICATIONS
Treatment and prevention of cellulite, “orange peel” appearance,
loss of skin compactness and smoothness.
PROPERTIES
Exposure® Dermatological Anticellulite Cream unique formulation
includes the patented liposomal complex, Liporeductyl®. The
potent anticellulite effects of Liporeductyl® have shown in
independent clinical trials to significantly increase skin elasticity,
compactness, smoothness and hydration in 4 weeks, and to reduce
skin fat mass, extracellular water and “orange peel” appearance
by the following mechanisms of action:
- lipolytic effect: provided by blockers
of AMPc lysis and lipase stimulators
- increased microcirculation effect:provided
by flavonoids and caffeine
- draining effect: provided by ivy
extract and carnitine
- cellulite prevention effect: inhibition
of adipocyte maturation facilitated by the GHK tripeptide
DIRECTIONS
Suitable for all skin types. Apply twice a day. Massage the affected
area with circular movements until complete cream absorption.
Regular use of Exposure® Dermatological Anticellulite Cream
with Liporeductyl® leads to significant results in 3-6 weeks,
depending on individuals and the extent of fatty deposits.
Exposure® Dermatological Anticellulite Cream with Liporeductyl® can
be used in conjunction with cellulite suction & rolling treatments
such as Endermologie®, with excellent results.
Wash hands thoroughly after use.
WARNING
Some patients experience breakouts any time they change their skin
care regimen. Skin reactions to any new cream, though rare, are
likely to occur within the first few days of use. If any reaction
occurs, wash the product off and discontinue use.
Topical use only. Do not apply to eyes, mucose tissues and/or open
wounds.
CONTRAINDICATIONS
Prior history of sensitivity or allergic reaction to this product
or any of its ingredients.
|
|
ADVERSE REACTIONS
No systemic adverse reactions have been reported. In rare cases, hypersensitivity
(localized contact dermatitis) may occur: cream application should be discontinued
and the physician notified immediately.
KEEP OUT OF THE REACH AND SIGHT OF CHILDREN
Not tested on animals
Manufactured in the EC for Medical Aesthetics Ltd., London, UK
BIBLIOGRAPHY
1. Anatomico-pathological causes
of cellulite. Merlen JF, Curri SB. J Mal Vasc. 1984;9 Suppl A:53.
2. Effects of GHK Tripeptide [glycyl-histidyl-lysyl chelated Cu(II)]
on ferritin dependent lipid peroxidation. Miller DM, DeSilva D,
Pickart L, Aust SD. Adv Exp Med Biol. 1990;264:79-84
3. Botanical extracts used in the treatment of cellulite.Hexsel
D, Orlandi C, Zechmeister do Prado D. Dermatol Surg. 2005 Jul;31(7
Pt 2):866-72; discussion 872.
4. Ingredients and safety of cellulite creams. Sainio EL, Rantanen
T, Kanerva L. Eur J Dermatol. 2000 Dec;10(8):596-603
5. Topical vitamins, minerals and botanical ingredients as modulators
of environmental and chronological skin damage. Chiu A, Kimball
AB. Br J Dermatol. 2003 Oct;149(4):681-91.
6. Cellulite: a review of its physiology and treatment. Avram MM.
J Cosmet Laser Ther. 2004 Dec;6(4):181-5.
7. A double-blind evaluation of the activity of an anti-cellulite
product containing retinol, caffeine, and ruscogenine by a combination
of several non-invasive methods. Bertin C, Zunino H, Pittet JC,
Beau P, Pineau P, Massonneau M, Robert C, Hopkins J. J Cosmet Sci.
2001 Jul-Aug;52(4):199-210.
8. Cosmeceutical peptides. Lupo MP. Dermatol Surg. 2005 Jul;31(7
Pt 2):832-6; discussion 836.
9. Cellulite: from standing fat herniation to hypodermal stretch
marks. Pierard GE, Nizet JL, Pierard-Franchimont C. Am J Dermatopathol.
2000 Feb;22(1):34-7.
10. Cellulite: a review. Rossi AB, Vergnanini AL. J Eur Acad Dermatol
Venereol. 2000 Jul;14(4):251-62.
11. Regulation of cell activity by the extracellular matrix: the
concept of matrikines. Maquart FX, Simeon A, Pasco S, Monboisse
JC. J Soc Biol. 1999;193(4-5):423-8.
12. Inhibition of chronic skin inflammation by topical anti-inflammatory
flavonoid preparation, Ato Formula. Lim H, Son KH, Chang HW, Kang
SS, Kim HP. Arch Pharm Res. 2006 Jun;29(6):503-7.
13. An exploratory investigation of the morphology and biochemistry
of cellulite.
Rosenbaum M, Prieto V, Hellmer J, Boschmann M, Krueger J, Leibel
RL, Ship AG. Plast Reconstr Surg. 1998 Jun;101(7):1934-9.
©2006 Medical Aesthetics Ltd. London (UK)
All rights reserved
Go Back
Email a friend
|
|
